FDA Clears Glooko’s Cloud-Based Insulin Dosing Platform

FDA clears Glooko’s cloud-based insulin dosing platform

Ideating on Glooko’s existing EndoTool system, the cloud-based version is designed to support more scalable deployment across hospital settings.The post FDA clears Glooko’s cloud-based insulin dosing platform appeared first on Medical Device Network.

Glooko Announces FDA 510(k) Clearance for EndoTool IV Cloud

EndoTool IV Cloud is the first FDA-cleared, cloud-based patient-specific insulin dosing platform, designed to support scalable deployment Commercial launch anticipated before the end of 2026PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that more... The post Glooko A…

Glooko wins FDA clearance for cloud-based insulin dosing platform

Glooko announced today that the FDA granted 510(k) clearance for its EndoTool IV Cloud, a cloud-based, patient-specific insulin dosing platform. Palo Alto, California-based Glooko describes the EndoTool IV Cloud as the first FDA-cleared platform of its kind. The cloud-based version of EndoTool IV, it offers a clinical decision support solution for intravenous insulin dosing in the hospital setting. It delivers proven insulin dosing capabilities …